Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

11
Bulletproof Investing Performance Update: Week 38

7h seekingalpha
It's been six months since I presented 4 hedged portfolios and 10 top names in week 38 of my Marketplace service (February 15th). Here's how everything did.
NFLX CMD CRI NVDA RHT DLTR CMN ATRA GWW ASGN EBIX ARW IPGP ABBV ABBV

10
Why Merrill Lynch Sees Health Care Sector Offering Solid Growth, and as Value and Defensive

2018-08-15 247wallst
Each month brings new views from firms on Wall Street. This includes the actively followed RIC Report from Merrill Lynch, showing views on many sectors and many markets for the firm’s clients. The monthly RIC Report is quite favorable on the health care sector as an opportunity for investors.
PFZ AMGN MRK A ABBV 500680 PFE PFIZER ABBV

44
Verastem: An Undervalued Rare Oncology Gem With Big Upcoming Catalysts

2018-08-15 seekingalpha
Duvelisib will be the only drug of its kind - a monotherapy PI3K dual inhibitor that can be taken orally at home without traveling to an infusion center.
INFI EXEL VSTM NVS YKLTF ABBV PFE ABBV

40
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review

2018-08-14 seekingalpha
Discussion: RedHill Biopharma (RDHL) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The notice allows the patent to be valid until at least 2029. Apart from Crohn’s Disease, the company has diverse program pipeline. The program includes other indications such as H. Pylori infection, migraine, and nontuberculous mycobacteria (NTM) infections.
MBIO REDIF APOP RDHL ACER ARQL MGTX STML CLRBZ CLRBW MCUJF ABBV CLRB APOPW ALNY ABBV VNRX

28
Is Cocrystal Beating The Dead Hepatitis C Horse?

2018-08-14 seekingalpha
Cocrystal believes that there is still a suitable market for their ultra-short Hepatitis C regimen despite an industry-wide exodus out of Hepatitis C.
VRTX OPK GILD TEVA TEVVF BITRF VRX TEVJF TBPH SBPH ABBV PTCT COCP BMY ABBV

25
Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More

2018-08-13 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features updated research reports on 16 major stocks, including Mastercard (MA), AbbVie (ABBV) and Twenty-First Century Fox (FOXA). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
FOX GD ZTO MA BXP TCO CVS FTV 7018 ALXN AMT CME PPL ABBV FOXA ABBV

38
Venture Capital Deals Of The Week: SoftBank Hands WeWork $1B

2018-08-11 seekingalpha
Welcome to Seeking Alpha’s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings.
NPSNY TEAM FB AVRO IPO TRIP SRPT BOLD GS GOOGL NVS MSFT ABBV PFE ABBV IPZYF EBAY

221
Stocks To Watch: Any Privacy For Tesla?

2018-08-11 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
SYY DCP DTK FOLD AROC ALLK CRL JWN WPZ STI-A CSCO CCB ABBV RUBY EQIX GILD CNST SYF CZR NVO JNJ MGM VRTX TM AXP NVDA BAC AGN HESM FAF KSU EFX CBU CREE LLY GSK JPM KHC TSLA PLAY DE OMP MYFW JCP TWX SYN SMLP WMT AMAT TWTR CELG WMB GSK VLKAY BAC DFS SQ IDXX BWLD ACOR STI ABBV NTAP CRNX PFE REPL JD HD WIMHY TLRY GM BMY CWH WIMHF F C ESTA A LYB CMCSA M COF WMH MRK LALWF SEMG

41
Stay Away From Coal Stocks - Cramer's Lightning Round (8/9/18)

2018-08-10 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, August 9.
DUKH DUK TRXC ISRG GDOT BPL AEP ABBV ED AAXN ABBV

69
Watchlist August 2018

2018-08-10 seekingalpha
It's time for the monthly watchlist report. As always, you can find the updated info at any time here Dividend Income Spreadsheet and the Portfolio Spreadsheet.
NLTBF AAPL ITW TSLA SBUX ABBV VITIF ABBV

12
Roche: Details On Growing Through The Patent Cliff (Part 2 Of 2)

2018-08-09 seekingalpha
Roche has implemented what I view as a brilliant strategy to do more than survive the patent expirations of its Big 3 drugs.
AMGN BIIB ABBV PFE ABBV

20
Bulletproof Investing Performance Update: Week 37

2018-08-09 seekingalpha
It's been six months since I presented 4 hedged portfolios and 10 top names in week 37 of my Marketplace service (February 8th). Here's how everything did.
GWW ASGN WLK AZO CTLR IPGP ABBV CLR ABBV EXAS FTNT

22
Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut

2018-08-08 zacks
Mylan (MYL - Free Report) reported dismal results for second-quarter 2018 as earnings and sales both missed estimates. The company also lowered its guidance.
GSK ABBV CVS GSK ABBV

9
Trump Forces Pharma to Face More Medicare Drug-Price Negotiation - Bloomberg

2018-08-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AMGN ABBV ABBV

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...